TII
8.12.2021 10:34:09 CET | Business Wire | Press release
The Secure Systems Research Centre (SSRC) at Technology Innovation Institute (TII), the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), today announced the launch of its first Reduced Instruction Set Computer (RISC-V) based drone flight controller that leverages the Centre’s own secure PX4 stack. The flight marks a milestone in SSRC’s path to making RISC-V based UAV systems a reality through this successful testing and validation of the RISC-V + the secure PX4 stack system.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211208005440/en/
Earlier this year, the Centre became a strategic member of RISC-V International, a non-profit organisation controlled by its members, which directs the future development and drives the adoption of RISC-V free and open Instruction Set Architecture (ISA). SSRC is focused on building an RISC-V based secure flight computer system. Today’s milestone is a major signpost on this path, with the Centre using a commercially available RISC-V development platform to port the DroneCode PX4 open source software to RISC-V.
Dr. Ray O. Johnson, CEO of TII, said: “RISC-V’s ISA is revolutionising the world of computing systems, and TII is proud to build this capability into our growing collection of breakthrough solutions that are future-proofing our world – one step at a time. We are seeing the use cases for drones and similar autonomous systems now spanning multiple sectors from e-commerce to healthcare and communication to security. This achievement will further strengthen our credibility as a global research centre at the forefront of cutting-edge technology that is working to shape an enabled and more secure world.”
Dr. Shreekant (Ticky) Thakkar, Chief Researcher, SSRC, said: “We are putting TII on the world map as leaders in pioneering Zero Trust Drone System research through this effort. The DroneCode community is the leading open-source community of PX4 Autopilot and fight controller hardware code and specification, respectively. A significant part of the work in realising this project required the porting of NuttX real-time OS and PX4 flight controller software to the RISC-V platform. SSRC has already included some of the planned security improvements into its existing PX4 software stack, and we will continue to develop this software and contribute the modifications back to open source.”
He added: “Through this milestone, we intend to highlight our regional expertise in the research and development of security for Drone and Autonomous Systems, an area that is set to have an outsized impact in shaping the Smart Cities of the future - making them safer and also significantly accelerating the opportunities for new services.”
As a follow-up, SSRC will continue to improve the security and resilience of the open source PX4 flight control software stack and NuttX real-time OS in collaboration with open source community. Furthermore, the Centre has presented a roadmap that includes improving memory protection of NuttX OS and PX4, protecting data on the removable media and utilising commercially available Root-of-Trust components.
Jukka Laitinen, Drone Software Lead Engineer and Architect at the SSRC in TII and Technical Lead for Dronecode Security Special Interest Group also presented a talk on making the current drone platform better, more secure, and resilient at the PX4 Autopilot Development Summit in September 2021.
SSRC is on track to achieving the first TII custom flight controller hardware, with the initial prototypes of this hardware, using a commercial off-the-shelf RISC-V SoC, expected by Q1 2022. This will enable researchers and industry to replace existing commercial flight controllers with a TII secure flight controller.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20211208005440/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
